Vivoryon Therapeutics N.V. reported earnings results for the full year ended December 31, 2021. For the full year, the company reported sales was EUR 10.76 million. Net loss was EUR 12.66 million compared to EUR 16.51 million a year ago. Basic loss per share from continuing operations was EUR 0.63 compared to EUR 0.83 a year ago.